Merck KGaA licenses oncology MAb in €0.5 billion deal with Symphogen
This article was originally published in Scrip
Executive Summary
Merck KGaA has signed an exclusive worldwide licence agreement for Symphogen's lead oncology candidate Sym004, a mix of two monoclonal antibodies that target the epidermal growth factor receptor (EGFR). The deal is worth a potential total of $500 million to the privately-held Danish biotechnology firm.